Search
×
FR

Placeholder headline

This is just a placeholder headline

API Technical Report TDB-6 Chapter 6 – Density

$

204

BUY NOW

Placeholder headline

This is just a placeholder headline

API STD 560: Fired Heaters for General Refinery Services

$

721

BUY NOW

Placeholder headline

This is just a placeholder headline

API STD 64: Diverter Equipment Systems

$

324

BUY NOW

Placeholder headline

This is just a placeholder headline

API MPMS CH 17.10.1: Refrigerated Light Hydrocarbon Fluids – Measurement of Cargoes on Board LNG Carries

$

417

BUY NOW

Placeholder headline

This is just a placeholder headline

API RP 13B-1: Testing Water-based Drilling Fluids

$

418

BUY NOW

Placeholder headline

This is just a placeholder headline

API Technical Report TDB-12 Chapter 12 – Thermal Conductivity

$

214

BUY NOW

Placeholder headline

This is just a placeholder headline

API 16FI Frac Iron Guidelines and Requirements

$

129

BUY NOW

ISO 24190:2023

ISO 24190:2023 Biotechnology – Analytical methods – Risk-based approach for method selection and validation for rapid microbial detection in bioprocesses

CDN $312.00

Description

This document provides guidance, a framework and a risk-based approach for the selection and validation of methods for rapid microbial detection in cellular therapeutic product manufacturing.

This document provides a flexible risk-based framework for the detection of microbial contamination in cellular therapeutic products and cellular intermediates.

This document provides general requirements and risks associated with cellular therapeutic product manufacturing, with flexibility to address differences in specific manufacturing processes of each unique cellular therapeutic product.

This document primarily addresses sterility testing in cellular therapeutic product manufacturing. This document is applicable to other cell-derived therapeutic product manufacturing.

This document focuses on rapid microbial test methods (RMTMs) used for both in-process and final product testing.

Viral testing in cellular therapeutic product manufacturing is not included in this document.

Edition

1

Published Date

2023-05-31

Status

PUBLISHED

Pages

44

Language Detail Icon

English

Format Secure Icon

Secure PDF

Abstract

This document provides guidance, a framework and a risk-based approach for the selection and validation of methods for rapid microbial detection in cellular therapeutic product manufacturing.

This document provides a flexible risk-based framework for the detection of microbial contamination in cellular therapeutic products and cellular intermediates.

This document provides general requirements and risks associated with cellular therapeutic product manufacturing, with flexibility to address differences in specific manufacturing processes of each unique cellular therapeutic product.

This document primarily addresses sterility testing in cellular therapeutic product manufacturing. This document is applicable to other cell-derived therapeutic product manufacturing.

This document focuses on rapid microbial test methods (RMTMs) used for both in-process and final product testing.

Viral testing in cellular therapeutic product manufacturing is not included in this document.

Previous Editions

Can’t find what you are looking for?

Please contact us at: